FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL
The U.S. Food and Drug Administration recently approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded …
Read More